Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00879411
First received: April 9, 2009
Last updated: February 28, 2014
Last verified: February 2014
  Purpose

Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients


Condition Intervention
Hypertension
Drug: Micardis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: 24h BP Under Micardis in Daily Practice

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Efficacy (Change of Systolic Blood Pressure) [ Time Frame: baseline to 8 weeks ]
    Change from baseline in 24h systolic blood pressure (BP) at week 8

  • Efficacy (Change of Diastolic Blood Pressure) [ Time Frame: baseline to 8 weeks ]
    Change from baseline in 24h diastolic blood pressure (BP) at week 8


Secondary Outcome Measures:
  • Overall Tolerability Scale [ Time Frame: 8 weeks ]
    Safety and tolerability of Micardis® in the treatment of patients with hypertension over 8 weeks, using 10 point Likert scale with worst score=1, best score=10


Enrollment: 670
Study Start Date: April 2009
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
arterial hypertension Drug: Micardis

  Eligibility

Ages Eligible for Study:   18 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

hypertensive patients

Criteria

Inclusion criteria:

  1. Patients who have recently been diagnosed with hypertension
  2. Patients whose current blood pressure treatment are inadequate and needs to be revised are suitable for inclusion.

Exclusion criteria:

None (according to investigator)

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00879411

Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00879411     History of Changes
Other Study ID Numbers: 502.582
Study First Received: April 9, 2009
Results First Received: January 18, 2012
Last Updated: February 28, 2014
Health Authority: Switzerland: Laws and standards

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases
Telmisartan
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014